Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Targeting deposits in amyloidosis

Ashutosh Wechalekar • 5 May 2020
Amyloidosis Rare Diseases Antibodies

Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, touches on future approaches for amyloidosis treatment, including targeting amyloid deposits with monoclonal antibodies as well as novel therapies targeting amyloidosis precursor proteins. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Ashutosh Wechalekar

9:53
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Ashutosh Wechalekar et al. • 9 Dec 2023
0:54
The potential of daratumumab alone or with CyBorD in patients with stage IV AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
1:07
The safety and efficacy of belantamab mafodotin in AL amyloidosis
Ashutosh Wechalekar • 12 Dec 2022
2:14
Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges
Ashutosh Wechalekar • 12 Dec 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals